Silence Therapeutics plc

Nasdaq SLN · London, United Kingdom

Works in Hematology · Metabolic & endocrine · Oncology

Silence Therapeutics plc is a clinical trial sponsor based in London, United Kingdom, listed as Nasdaq SLN. It has 1 active clinical trial with 69 planned participants, in Hematology, Metabolic & endocrine and Oncology. Since 2021 it has completed 4 trials and stopped 0 early.

Trial track record · since 2021

1Active trials69 planned participants
4Completed1 with results posted
0Stopped earlyterminated, withdrawn or suspended

Financials · Nasdaq SLN

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 1 active trial

StageTrialStatus

Questions about Silence Therapeutics plc

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-12-19.

Approve Suite is not affiliated with Silence Therapeutics plc.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.